Drug intelligence / Profile preview

CS3005

Development stage: Phase 1
Lead developer: CStone Pharmaceuticals
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral

Overview

CS3005 is an orally bioavailable small molecule immune checkpoint inhibitor that acts as an antagonist of the adenosine A2A receptor (A2AR, also known as ADORA2A). By selectively binding to and inhibiting A2AR expressed on T lymphocytes, CS3005 modulates the tumor immune microenvironment, potentially enhancing antitumor immune responses. It is being developed primarily for the treatment of advanced solid tumors and other neoplasms. The drug was discovered and initially developed by CStone Pharmaceuticals[1][3].

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on CS3005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS3005.

Explore the full profile